RECRUITING

A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The main goal of this study is to screen and detect pancreatic cancer and precursor lesions in individuals with a strong family history or genetic predisposition to pancreatic cancer. Magnetic Resonance Imaging and Magnetic cholangiopancreatography (MRI/MRCP) will be utilized to screen for early stage pancreatic cancer or precursor lesions. Participants will be asked to donate a blood sample at specific intervals for the creation of a bio-bank necessary for the development of a blood based screening test for Pancreatic Cancer.

Official Title

A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals

Quick Facts

Study Start:2016-11
Study Completion:2026-11
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03250078

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:50 Years to 90 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. 1. Prior history of pancreatic cancer.
  2. 2. Presence of metastatic cancer or cancer requiring adjuvant chemotherapy within the past 5 years.
  3. 3. Received chemotherapy within the past 6 months. (Hormonal therapy is allowable if the disease free interval is at least 5 years).
  4. 4. Hereditary pancreatitis.
  5. 5. eGFR \< 30 mL/min
  6. 6. Contraindication to MRI examination or gadolinium contrast.
  7. 7. Pregnant or nursing women.
  8. 8. Co-morbid illnesses or other concurrent disease which, in the judgment of the clinicians obtaining informed consent, would make the participant inappropriate for entry into this study.

Contacts and Locations

Study Contact

Tammy Lo, APRN
CONTACT
Tammy.Lo@nuvancehealth.org
Pramila Krumholtz, RN
CONTACT
Pramila.Krumholtz@nuvancehealth.org

Principal Investigator

Richard Frank, MD
PRINCIPAL_INVESTIGATOR
Nuvance Health

Study Locations (Sites)

Nuvance Health
Norwalk, Connecticut, 06856
United States

Collaborators and Investigators

Sponsor: Nuvance Health

  • Richard Frank, MD, PRINCIPAL_INVESTIGATOR, Nuvance Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2016-11
Study Completion Date2026-11

Study Record Updates

Study Start Date2016-11
Study Completion Date2026-11

Terms related to this study

Keywords Provided by Researchers

  • Pancreas
  • Cancer
  • MRI
  • BRCA
  • Early Detection
  • Genetics
  • ATM
  • PALB2
  • Lynch
  • CDKN2A

Additional Relevant MeSH Terms

  • Pancreatic Neoplasms